Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MC2 32

Next Previous
Drug Profile

MC2 32

Alternative Names: BEBT-305; CU-0305; CUDC-305; DEBIO 0932; Debio-0932; MC2-32; RGRN-305

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Curis
  • Developer Curis; Debiopharm; MC2 Therapeutics; Regranion
  • Class 2 ring heterocyclic compounds; Anti-inflammatories; Antipsoriatics; Benzodioxoles; Imidazoles; Pyridines; Skin disorder therapies; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hidradenitis suppurativa
  • Phase Unknown Atopic dermatitis; Bullous pemphigoid
  • No development reported Plaque psoriasis
  • Discontinued Cancer; Lymphoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Plaque-psoriasis in Denmark (PO)
  • 13 May 2024 MC2 Therapeutics receives positive feedback from a pre-IND meeting with the US FDA with respect to its MC2 32 for Hidradenitis Suppurativa
  • 13 May 2024 MC2 Therapeutics plans to file an IND for MC2 32 in Hidradenitis suppurativa in mid-2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top